BACKGROUND: Several studies examined the influence of subthalamic nucleus-deep brain stimulation (STN-DBS) on quality of life (QoL) in patients with Parkinson's disease (PD). However, it is unclear whether this effect differs between age groups and disease durations and whether it stays consistent over time. OBJECTIVES: We assessed the influence of stimulation duration, disease duration, and age at surgery on QoL after STN-DBS. METHODS: We systematically searched for studies reporting the results of the Parkinson's Disease Questionnaire 39 or 8. Studies were included if they investigated the time passed since STN-DBS or if their study cohort fell into the range of one of the following age groups: younger than 60 years or between 60 and 70 years. For each condition, a standardized mean difference meta-analysis was performed. Furthermore, all studies were categorized into short or long disease duration at surgery using a median split. RESULTS: A total of 23 studies reporting the cumulative outcome of 76 to 802 PD patients were included in this analysis. The results demonstrate a substantial improvement of QoL after DBS that remains stable over 36 months. QoL falls to preoperative scores 60 months after surgery. However, only 3 studies could be included in this analysis. Both younger and older PD patients profit in QoL from STN-DBS, independent of the disease duration. CONCLUSIONS: The results of this analysis show an impressive improvement in QoL after STN-DBS, with a loss of QoL 60 months after DBS surgery. This highlights the need to explore the factors influencing QoL after STN-DBS to prevent or delay a decline in QoL.
BACKGROUND: Several studies examined the influence of subthalamic nucleus-deep brain stimulation (STN-DBS) on quality of life (QoL) in patients with Parkinson's disease (PD). However, it is unclear whether this effect differs between age groups and disease durations and whether it stays consistent over time. OBJECTIVES: We assessed the influence of stimulation duration, disease duration, and age at surgery on QoL after STN-DBS. METHODS: We systematically searched for studies reporting the results of the Parkinson's Disease Questionnaire 39 or 8. Studies were included if they investigated the time passed since STN-DBS or if their study cohort fell into the range of one of the following age groups: younger than 60 years or between 60 and 70 years. For each condition, a standardized mean difference meta-analysis was performed. Furthermore, all studies were categorized into short or long disease duration at surgery using a median split. RESULTS: A total of 23 studies reporting the cumulative outcome of 76 to 802 PD patients were included in this analysis. The results demonstrate a substantial improvement of QoL after DBS that remains stable over 36 months. QoL falls to preoperative scores 60 months after surgery. However, only 3 studies could be included in this analysis. Both younger and older PD patients profit in QoL from STN-DBS, independent of the disease duration. CONCLUSIONS: The results of this analysis show an impressive improvement in QoL after STN-DBS, with a loss of QoL 60 months after DBS surgery. This highlights the need to explore the factors influencing QoL after STN-DBS to prevent or delay a decline in QoL.
Entities:
Keywords:
Parkinson's disease; age; deep brain stimulation; follow‐up time; quality of life
Authors: Günther Deuschl; Carmen Schade-Brittinger; Paul Krack; Jens Volkmann; Helmut Schäfer; Kai Bötzel; Christine Daniels; Angela Deutschländer; Ulrich Dillmann; Wilhelm Eisner; Doreen Gruber; Wolfgang Hamel; Jan Herzog; Rüdiger Hilker; Stephan Klebe; Manja Kloss; Jan Koy; Martin Krause; Andreas Kupsch; Delia Lorenz; Stefan Lorenzl; H Maximilian Mehdorn; Jean Richard Moringlane; Wolfgang Oertel; Marcus O Pinsker; Heinz Reichmann; Alexander Reuss; Gerd-Helge Schneider; Alfons Schnitzler; Ulrich Steude; Volker Sturm; Lars Timmermann; Volker Tronnier; Thomas Trottenberg; Lars Wojtecki; Elisabeth Wolf; Werner Poewe; Jürgen Voges Journal: N Engl J Med Date: 2006-08-31 Impact factor: 91.245
Authors: J C Gómez-Esteban; J J Zarranz; E Lezcano; B Tijero; A Luna; F Velasco; I Rouco; I Garamendi Journal: Eur Neurol Date: 2007-01-10 Impact factor: 1.710
Authors: Kenneth A Follett; Frances M Weaver; Matthew Stern; Kwan Hur; Crystal L Harris; Ping Luo; William J Marks; Johannes Rothlind; Oren Sagher; Claudia Moy; Rajesh Pahwa; Kim Burchiel; Penelope Hogarth; Eugene C Lai; John E Duda; Kathryn Holloway; Ali Samii; Stacy Horn; Jeff M Bronstein; Gatana Stoner; Philip A Starr; Richard Simpson; Gordon Baltuch; Antonio De Salles; Grant D Huang; Domenic J Reda Journal: N Engl J Med Date: 2010-06-03 Impact factor: 91.245
Authors: Frances M Weaver; Kenneth Follett; Matthew Stern; Kwan Hur; Crystal Harris; William J Marks; Johannes Rothlind; Oren Sagher; Domenic Reda; Claudia S Moy; Rajesh Pahwa; Kim Burchiel; Penelope Hogarth; Eugene C Lai; John E Duda; Kathryn Holloway; Ali Samii; Stacy Horn; Jeff Bronstein; Gatana Stoner; Jill Heemskerk; Grant D Huang Journal: JAMA Date: 2009-01-07 Impact factor: 56.272